Cadrenal Therapeutics, Inc. Common Stock (CVKD) — Financial Flexibility Index

Latest as of March 2026: -2.82x

Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a Financial Flexibility Index of -2.82x as of March 2026. Free cash flow of $-3.00 Million (operating CF $-3.00 Million minus capex $3.00) represents -3% of total liabilities ($1.06 Million). Check Cadrenal Therapeutics, Inc. Common Stock (CVKD) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Financial Flexibility Index

-2.82x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-3.00 Million
Operating CF − Capex

Total Liabilities

$1.06 Million
USD

Capital Expenditures

$3.00
USD

Cadrenal Therapeutics, Inc. Common Stock Financial Flexibility Index (2022–2025)

Historical Financial Flexibility Index trend for Cadrenal Therapeutics, Inc. Common Stock across 4 annual periods. For the full cash flow conversion analysis, see CVKD cash generation efficiency.

Annual Financial Flexibility Index for Cadrenal Therapeutics, Inc. Common Stock (2022–2025)

Year-by-year free cash flow to debt coverage for Cadrenal Therapeutics, Inc. Common Stock. Explore CVKD debt coverage from operations to assess how comfortably operating cash covers total debt obligations.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -7.93x $-12.60 Million $-12.60 Million $1.59 Million ▼ -189.6%
2024 -2.74x $-7.35 Million $-7.36 Million $2.68 Million ▲ +35.8%
2023 -4.27x $-3.53 Million $-3.53 Million $826.88K ▼ -2145.6%
2022 -0.19x $-1.20 Million $-1.20 Million $6.33 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities